Home > Publications Database > Cost-Effectiveness of a Digitally Supported Care Management Program for Caregivers of People With Dementia. > print

001     277790
005     20250409095952.0
024 7 _ |a 10.1016/j.jval.2025.01.011
|2 doi
024 7 _ |a pmid:39922302
|2 pmid
024 7 _ |a 1098-3015
|2 ISSN
024 7 _ |a 1524-4733
|2 ISSN
024 7 _ |a altmetric:174035216
|2 altmetric
037 _ _ |a DZNE-2025-00468
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Pfaff, Michelle
|0 P:(DE-2719)9002113
|b 0
|e First author
|u dzne
245 _ _ |a Cost-Effectiveness of a Digitally Supported Care Management Program for Caregivers of People With Dementia.
260 _ _ |a Amsterdam [u.a.]
|c 2025
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1743594413_9485
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a To examine the cost-effectiveness of a digitally supported care management system (CMS) for caregivers of people with dementia (PwD) compared with usual care.The analysis was based on 192 caregivers (n = 96 CMS, n = 96 usual care) of PwD in a cluster-randomized controlled trial testing a digitally supported CMS, aiming to identify and address caregivers' unmet needs and develop and implement an individualized support and care plan over 6 months. Incremental costs from the public-payer and societal perspectives, quality-adjusted life years (QALY), and the incremental cost-effectiveness ratio 6 months after baseline were calculated using multivariate regression models. We assessed the probability of cost-effectiveness using a range of willingness-to-pay thresholds.Caregivers in the intervention group gained QALYs (+0.004 [95% CI -0.003 to 0.012], P value = .225) and had lower costs from the public payer (-378€ [1926-1168], P value = .630), but higher costs from the societal perspective (+1324 [-3634 to 6284], P value = .599). The intervention dominated usual care from the payer perspective, whereas the incremental cost-effectiveness ratio was €331 000/QALY from a societal perspective. The probability of cost-effectiveness was 72% and 79% from the public payer and 33% and 35% from a societal perspective at the willingness-to-pay thresholds threshold of €40 000 and €80 000/QALY gained.CMS was likely cost-effective from the payer but not from a societal perspective, underlining the importance of informal care. The gain in QALY was marginal and could be due to the short observation period. Focusing on both the caregiver and the PwD, rather than assessing the PwD needs through the caregiver, could improve the cost-effectiveness results.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a caregiver support
|2 Other
650 _ 7 |a collaborative care
|2 Other
650 _ 7 |a cost-effectiveness
|2 Other
650 _ 7 |a dementia
|2 Other
650 _ 7 |a informal care
|2 Other
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Cost-Benefit Analysis
|2 MeSH
650 _ 2 |a Caregivers: economics
|2 MeSH
650 _ 2 |a Dementia: economics
|2 MeSH
650 _ 2 |a Dementia: therapy
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Quality-Adjusted Life Years
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Aged, 80 and over
|2 MeSH
650 _ 2 |a Health Care Costs
|2 MeSH
700 1 _ |a Hoffmann, Wolfgang
|0 P:(DE-2719)2000040
|b 1
|u dzne
700 1 _ |a Boekholt, Melanie
|0 P:(DE-2719)9000494
|b 2
|u dzne
700 1 _ |a Biernetzky, Olga
|0 P:(DE-2719)9000616
|b 3
|u dzne
700 1 _ |a Blotenberg, Iris
|0 P:(DE-2719)9001870
|b 4
|u dzne
700 1 _ |a Afrin, Dilshad
|0 P:(DE-2719)9001035
|b 5
700 1 _ |a Platen, Moritz
|0 P:(DE-2719)9001238
|b 6
|u dzne
700 1 _ |a Teipel, Stefan
|0 P:(DE-2719)2000026
|b 7
|u dzne
700 1 _ |a Thyrian, Jochen René
|0 P:(DE-2719)2290613
|b 8
|u dzne
700 1 _ |a Kilimann, Ingo
|0 P:(DE-2719)2810394
|b 9
|u dzne
700 1 _ |a Michalowsky, Bernhard
|0 P:(DE-2719)2810763
|b 10
|e Last author
|u dzne
773 _ _ |a 10.1016/j.jval.2025.01.011
|g Vol. 28, no. 4, p. 527 - 535
|0 PERI:(DE-600)2011039-X
|n 4
|p 527 - 535
|t Value in health
|v 28
|y 2025
|x 1098-3015
856 4 _ |u https://pub.dzne.de/record/277790/files/DZNE-2025-00468%20SUP.zip
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/277790/files/DZNE-2025-00468.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/277790/files/DZNE-2025-00468.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:277790
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)9002113
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)2000040
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)9000494
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)9000616
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)9001870
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)9001035
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)9001238
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)2000026
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 8
|6 P:(DE-2719)2290613
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)2810394
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 10
|6 P:(DE-2719)2810763
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0130
|2 StatID
|b Social Sciences Citation Index
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-20
915 _ _ |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
|0 LIC:(DE-HGF)CCBYNCND4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b VALUE HEALTH : 2022
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1180
|2 StatID
|b Current Contents - Social and Behavioral Sciences
|d 2024-12-20
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-20
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2024-12-20
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-20
920 1 _ |0 I:(DE-2719)5000067
|k AG Michalowsky
|l Patient-Reported Outcomes and Health Economics Research
|x 0
920 1 _ |0 I:(DE-2719)1510600
|k AG Hoffmann
|l Translational Health Care Research
|x 1
920 1 _ |0 I:(DE-2719)1510100
|k AG Teipel
|l Clinical Dementia Research (Rostock /Greifswald)
|x 2
920 1 _ |0 I:(DE-2719)1510800
|k AG Thyrian
|l Interventional Health Care Research (IHCR)
|x 3
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)5000067
980 _ _ |a I:(DE-2719)1510600
980 _ _ |a I:(DE-2719)1510100
980 _ _ |a I:(DE-2719)1510800
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21